<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/2020/3196375</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Lianhua-Qingwen Displays Antiviral and Anti-Inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Chunguang</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yutao</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Jiayang</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Wen</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Haiming</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Qiaolian</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2681-4171</contrib-id><name><surname>Yang</surname><given-names>Zifeng</given-names></name><email>jeffyah@163.com</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China</aff><aff id="I2">
<sup>2</sup>College of Health Education, Guangdong Pharmaceutical University, Guangzhou 510006, China</aff><aff id="I3">
<sup>3</sup>The First Hospital of Yulin, Yulin 719000, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Mark Moss</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>5</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>6</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>2020</volume><elocation-id>3196375</elocation-id><history><date date-type="received"><day>21</day><month>12</month><year>2019</year></date><date date-type="rev-recd"><day>20</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Chunguang Yang et al.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Influenza B virus (IBV) is one of the main pathogens of the annual influenza epidemic, and the disease burden is significant, especially among children and young teenagers. In this study, the antiviral and anti-inflammatory effects of a traditional Chinese medicine prescription, the Lianhua-Qingwen capsule, were evaluated. Our results showed that Lianhua-Qingwen capsule can inhibit both Victoria and Yamagata lineages, and the 50% inhibitive concentrations ranged from 0.228&#x02009;&#x000b1;&#x02009;0.150 to 0.754&#x02009;&#x000b1;&#x02009;0.161&#x02009;mg/mL. The time course results demonstrated that IBV yields were reduced with treatment at 0&#x02013;4&#x02009;h after infection, and the mechanistic research verified that Lianhua-Qingwen capsule has hemagglutination inhibition activity against B/Guangzhou/0215/2012 but not A/California/04/2009. In addition to antiviral activity, Lianhua-Qingwen capsule can also inhibit excessive expression of RANTES, IL-6, IL-8, IP-10, TNF-<italic>&#x003b1;</italic>, MCP-1, MIP-1<italic>&#x003b2;</italic>, and IFN-<italic>&#x003bb;</italic> at the mRNA level and prevent a severe inflammatory response. The in vivo results confirmed that orally administered Lianhua-Qingwen capsule (100&#x02013;400&#x02009;mg/kg/day) does not reduce IBV-induced lung viral load and mortality in mice. However, the pathological change in lungs was alleviated, and there were fewer inflammatory cells in the lungs of Lianhua-Qingwen capsule treated mice than those in controls. Further research confirmed that the combination treatment of 200&#x02009;mg/kg/day of Lianhua-Qingwen capsule with 2&#x02009;mg/kg/day of oseltamivir significantly reduced IBV infection over the individual administration of either alone in vivo. Our findings prove that Lianhua-Qingwen capsule could be used as an assistant medicine to enhance the effect of oseltamivir against influenza B virus infection.</p></abstract><funding-group><award-group><funding-source>Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Shijiazhuang, China)</funding-source></award-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>NSFC-FDCT-81661168012</award-id></award-group><award-group><funding-source>Guangdong Science and Technology Department</funding-source><award-id>2013B051000085</award-id></award-group><award-group><funding-source>Engineering Technology Research Center (Development) of Guangdong General Universities</funding-source><award-id>GCZX-A1408</award-id></award-group><award-group><funding-source>Natural Science Basic Research Program of Shaanxi</funding-source><award-id>2019JM-513</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Influenza B virus (IBV), one of the main pathogens of annual influ enza epidemics, is divided into two genetically and antigenically distinct lineages, B/Victoria/2/1987-like (Victoria) and B/Yamagata/16/1988-like (Yamagata). Both lineages of IBVs circulate or cocirculate globally with the H1N1 or H3N2 subtype of influenza A viruses (IAVs) in annual seasonal epidemics. The proportion of IBV infection cases out of total influenza-positive cases varies from approximately 1% to 40% in a single epidemic.</p><p>The pathogenicity and severity of IBV are weaker than those of IAV, but the disease burden of IBV is significant, especially among children and young teenagers [<xref rid="B1" ref-type="bibr">1</xref>]. In a report on mortality related to influenza between 1976 and 1999 in the USA, the highest mortality was associated with H3N2, followed by IBV and then H1N1 [<xref rid="B2" ref-type="bibr">2</xref>]. During 2003&#x02013;2008, the mortality attributable to IBV was estimated to be higher than that to H3N2 or H1N1 in China [<xref rid="B3" ref-type="bibr">3</xref>]. Furthermore, influenza B virus caused more complications, including neurological, muscular manifestations [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>] and cardiologic complications [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>].</p><p>Antiviral drugs play an important role in the prevention and treatment of IBV. The neuraminidase inhibitors (NAI) include oseltamivir, intravenously injected peramivir, and inhalational zanamivir. However, recent clinical studies suggest that oseltamivir is less effective in treating IBV than IAV [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>]. Additionally, in clinical studies in Japan, when more than 100 children with influenza B or influenza A (H3N2) were administered oseltamivir, the results showed that oseltamivir was less effective for influenza B than influenza A in reducing the time the virus lasted or duration of fever [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>].</p><p>In 2009, the Chinese government recommended traditional Chinese medicine (TCM) prescriptions of Lianhua-Qingwen capsule (LQ) as a candidate formula to treat and control the H1N1 pandemic. This new formula is a natural herbal medicine developed from two classical TCM formulae, <italic>Yinqiao San</italic> and <italic>Maxing Shigan Tang,</italic> which have been used historically for treatment of influenza-like illness in China [<xref rid="B13" ref-type="bibr">13</xref>]. When a randomized, double-blind, positive-controlled clinical trial of LQ anti-influenza A (H1N1) virus treatment was performed in China, the results confirmed that it was able to alleviate the symptoms significantly and achieve the same effect as oseltamivir [<xref rid="B14" ref-type="bibr">14</xref>]. LQ was approved for clinical trials as treatment for influenza infection by the FDA in 2016. In addition, our previous results also demonstrated that LQ could inhibit different strains of influenza A viruses and that it also suppressed virus-induced NF-kB activation and alleviated virus-induced cytokine expression [<xref rid="B15" ref-type="bibr">15</xref>].</p><p>There are several studies on the prospective antiviral drugs against influenza A virus, but very little have focused on IBV. The damage caused by IBV has become prohibitive. Based on the previously established LQ clinical curative effect and experimental data on influenza A virus, in this study, the effects of LQ against influenza B virus in vitro and in vivo have been evaluated.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Drugs</title><p>The Lianhua-Qingwen capsule material (Lot No. B1602001) was provided by Shijiazhuang Yiling Pharmaceutical Co., Ltd (Shijiazhuang city, China). The drug was dissolved by DMSO into 500&#x02009;mg/mL and diluted using MEM to operational concentration before experiment (in vitro). Oseltamivir was obtained from Roche Co., Ltd. (Basel, Switzerland). Ribavirin was purchased from Star Lake Bioscience Co., Ltd. (Zhaoqing city, China).</p></sec><sec id="sec2.2"><title>2.2. Viruses and Cells</title><p>Influenza B virus (B/Lee/40) was purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). B/Guangzhou/GIRD08/2009 (Victoria-like), B/Guangzhou/GIRD01/2016 (Victoria-like), and B/Guangzhou/0215/2012 (Victoria-like) were isolated from clinical samples. Influenza B virus B/Guangzhou/19/2016 (Yamagata-like) was gifted by Dr. Feng Ye (the First Affiliated Hospital of Guangzhou Medical University). Influenza A virus A/California/04/2009 was gifted by professor Malik J. S. Peilis (WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong Special Administrative Region). All the viruses were cultured in MDCK (Madin-Darby canine kidney, ATCC), and all the cells were grown in Dulbecco's modified Eagle's medium (DMEM, Gibco) with 10% heat-inactivated fetal calf serum (FCS, Gibco).</p></sec><sec id="sec2.3"><title>2.3. Cytotoxicity</title><p>The cytotoxicity of LQ to MDCK cells was assessed via MTT assay, and 1&#x02009;&#x000d7;&#x02009;10<sup>4</sup> cells were seeded into 96-well plate. After incubation for 18&#x02009;h, the culture medium was removed, and the cells were washed once with PBS. A series of 2-fold dilutions of concentrations of LQ (maximum concentration of 10&#x02009;mg/mL) were then added to the wells, and the cells were incubated at 37&#x000b0;C, 5% CO<sub>2</sub>, for 48&#x02009;h. The medium was replaced with 1&#x02009;mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-PBS solution (100&#x02009;<italic>&#x003bc;</italic>L/well). The plate was incubated at 37&#x000b0;C for 4&#x02009;h, the solution was then replaced with DMSO, and the ODs value was measured in 570&#x02009;nm of wave after a gentle shaking. Three independent MTT assays were performed. The 50% toxicity concentration (TC<sub>50</sub>) was obtained via linear regression, and the result is shown as the mean&#x02009;&#x000b1;&#x02009;standard deviation (SD).</p></sec><sec id="sec2.4"><title>2.4. Virus Yield Reduction Assay</title><p>Anti-IBV activity was evaluated by cytopathogenic effect (CPE) and MTT assays. Confluent monolayers of MDCK cells in 96-well plates were inoculated with virus (0.01 MOI). After 2&#x02009;h, the inoculums were replaced with test medium containing a series of concentrations of LQ or DMSO (less than 1%) with 1&#x02009;<italic>&#x003bc;</italic>g/ml tosyl-phenylalanine chloromethyl-ketone (TPCK) treated trypsin (Sigma), 100&#x02009;U/ml penicillin, and 100&#x02009;<italic>&#x003bc;</italic>g/ml streptomycin (Gibco). The plate was incubated at 34&#x000b0;C, 5% CO<sub>2</sub>, for 72&#x02009;h. The inhibition rates were measured via MTT assay. Three independent tests were conducted, and the 50% inhibition concentration (IC<sub>50</sub>) was obtained via the Reed-Muench method [<xref rid="B16" ref-type="bibr">16</xref>].</p></sec><sec id="sec2.5"><title>2.5. Time Course Assay</title><p>The most effective concentration of the LQ in IBVs was tested by cytopathic effect (CPE). Three infection models were constructed. Before infection, 10<sup>6</sup> TCID<sub>50</sub> of virus was mixed with LQ and incubated at 37&#x000b0;C for 1&#x02009;h (<italic>pretreatment of virus, Pre-V</italic>); before infection, cells were treated with LQ for 1&#x02009;h at 37&#x000b0;C (<italic>pretreatment of cells, Pre-C)</italic>. LQ was used to treat cells at 2&#x02009;h after infection (<italic>posttreatment of virus, Post-V</italic>). The supernatant was collected at 24&#x02009;h postinfection, and the virus titers were determined in MDCK cells.</p><p>In <italic>Post-V</italic> model, MDCK cells were inoculated with B/Guangzhou/0215/2012 (MOI&#x02009;=&#x02009;0.1) at 4&#x000b0;C for 2&#x02009;h, and the viral solution was removed after washing twice with cold PBS. The medium containing 1&#x02009;<italic>&#x003bc;</italic>g/mL TPCK treated trypsin was added, and the cell plate was transferred and incubated at 37&#x000b0;C, 5% CO<sub>2</sub>, which was defined as 0&#x02009;h at this time. Then, 0.6&#x02009;mg/mL LQ was added at 0&#x02009;h, 2&#x02009;h, 4&#x02009;h, 6&#x02009;h, and 8&#x02009;h; the supernatant was collected at 12&#x02009;h, and the virus titer was detected subsequently in MDCK cells.</p></sec><sec id="sec2.6"><title>2.6. The Synthesis of Nucleoprotein</title><p>MDCK cells on treated coverslips were inoculated with B/Guangzhou/0215/2012 (1 MOI) at 4&#x000b0;C for 2&#x02009;h; then, the supernatant was removed, and the cells were washed twice with cold PBS. Next, 0.6&#x02009;mg/mL LQ or the same concentration of DMSO was added to cells at 0&#x02009;h after infection. The supernatant was removed at 8&#x02009;h after infection, and the coverslips were prepared for use in the immunofluorescence assay by washing twice.</p></sec><sec id="sec2.7"><title>2.7. Hemagglutination Inhibition Assay</title><p>Then, 25&#x02009;<italic>&#x003bc;</italic>L of series concentrations of LQ was mixed with an equivalent of eight hemagglutination units of virus solution. The plate was incubated at 37&#x000b0;C for 1&#x02009;h, and then 50&#x02009;<italic>&#x003bc;</italic>L of 0.5% chicken erythrocyte suspension was added. The hemagglutination inhibition activity of LQ was defined in complete inhibition of influenza virus hemagglutination activity after incubation for 40&#x02009;min at room temperature.</p></sec><sec id="sec2.8"><title>2.8. Viral Binding Assay</title><p>Next, 1&#x02009;&#x000d7;&#x02009;10<sup>3</sup> cells were seeded in 24-well culture plate with coverslips. The medium was removed after incubation for 18&#x02009;h; cells were washed with cold PBS. The mixture containing a selected concentration of LQ and virus (10 MOI), which were incubated at 37&#x000b0;C for 1&#x02009;h, was added to cells, and the cells were incubated at 4&#x000b0;C for 90&#x02009;min. The mixture was removed; the cells were washed with cold PBS three times. The viral binding was measured using an immunofluorescence assay.</p></sec><sec id="sec2.9"><title>2.9. Immunofluorescence Assay</title><p>The cells were fixed with 4% paraformaldehyde (v/v) at room temperature for 30&#x02009;min; the membrane was permeabilized with 0.5% (v/v) of Triton X-100 and then blocked with 50&#x02009;mg/mL of goat serum (Sigma) for 30&#x02009;min. Next, 1&#x02009;<italic>&#x003bc;</italic>g/mL of mouse monoclonal antibody (Abcam) against influenza virus nucleoprotein was added to the cells and incubated at 4&#x000b0;C overnight. After three washes, 10&#x02009;<italic>&#x003bc;</italic>g/mL of FITC-conjugated goat anti-mouse IgG antibody (Abcam) was added, and the cells were then incubated at 37&#x000b0;C for 90&#x02009;min. After washing, the nucleus was stained with 5&#x02009;ng/mL of DAPI for 5&#x02009;min. The slips were mounted, and the results were obtained under fluorescence confocal microscopy (Nikon, D-ECLIPSE C1-S1).</p></sec><sec id="sec2.10"><title>2.10. Real-Time PCR Assay</title><p>A549 cells growing in 96-well plates at 37&#x000b0;C, 5% CO<sub>2</sub>, were prepared and then infected with influenza B virus (B/Guangzhou/0215/2012, 0.1 MOI) for 2&#x02009;h. The inoculums were removed, and the cells were treated with 0.15, 0.3, and 0.6&#x02009;mg/mL of LQ. The cells were collected at 24&#x02009;h after infection, the total RNA was extracted using the TRIZOL reagent (Invitrogen), and cDNA was synthesized using PrimeScript&#x02122; RT Master Mix (perfect real time) (TAKARA). The expression of IFN-<italic>&#x003b1;</italic>/<italic>&#x003b2;</italic>/<italic>&#x003bb;</italic>1, CCL5/RANTES, IL-6, CXCL8/IL-8, CXCL10/IP-10, TNF-<italic>&#x003b1;</italic>, CCL2/MCP-1, CCL3/MIP-1<italic>&#x003b1;</italic>, CCL4/MIP-1<italic>&#x003b2;</italic>, IL-10, and IL-13 genes and reference GAPDH gene was detected using TB Green&#x02122; <italic>Premix Ex Taq</italic>&#x02122; II (TAKARA) by the ABI 7500 Real-Time PCR System [<xref rid="B17" ref-type="bibr">17</xref>].</p></sec><sec id="sec2.11"><title>2.11. Animal Experiment</title><p>Five-week-old, special-pathogen-free, female BALB/c mice were purchased from Guangdong Medical Laboratory Animal Center (Foshan city, Guangdong province, China, SCXK(G) 2008&#x02013;0002), The animals were fed a standard laboratory diet and provided water ad libitum. The animal experiments were performed in accordance with the Guidelines of Guangdong Regulation for the Administration of Laboratory Animals. The experiment was performed after two days of feeding. The animal experiments in this study have been allowed by the ethics committee. Before animal experiment, the 50% lethal dose (LD<sub>50</sub>) of B0215 virus was measured by survival, and 10 mice/dose were inoculated with 6 doses of 10-fold dilution of virus and observed for 15 days.</p><p>To assess the survival rate of LQ treated virally infected mice, 60 mice were divided into 6 groups (placebo, ribavirin 75&#x02009;mg/kg/day, LQ 100/200/400&#x02009;mg/kg/day, uninfected control, <italic>n</italic>&#x02009;=&#x02009;10): 5 groups (placebo, ribavirin 75&#x02009;mg/kg/day, LQ 100/200/400&#x02009;mg/kg/day) were inoculated with 5-fold 50% lethal dose (LD<sub>50</sub>) of B0215; control group was inoculated with equivalent solution without virus. The drugs were administered at 4&#x02009;h before infection and continued for 5 days once per day, with equivalent PBS given as placebo and control (Ctrl). Survival was evaluated 15 days after infection.</p><p>To evaluate the effect of LQ on viral yield in vivo, 30 mice (6 mice each in 5 groups) were infected with 10-fold LD<sub>50</sub> of B/Guangzhou/0215/2012 (B0215) via nose. Oral medicines or PBS (placebo) was administered to infected mice (<italic>n</italic>&#x02009;=&#x02009;6) for five days. Then, the mice were sacrificed, and the lungs were obtained on the 6th day of titer and pathological examination.</p><p>The effects of combinations of LQ and oseltamivir in the influenza B virus mouse model were also studied. 60 mice were divided into 10 groups (control, placebo, 200&#x02009;mg/kg/day of LQ, 2/10/50&#x02009;mg/kg/day of oseltamivir, 200&#x02009;mg/kg/day of LQ combined with 2/10/50&#x02009;mg/kg/day of oseltamivir respectively, <italic>n</italic>&#x02009;=&#x02009;6). Mice except control group were infected with 10-fold LD<sub>50</sub> B0215, and control group were inoculated with equivalent solution without virus. Mice were treated with oseltamivir alone or combined with LQ from 4&#x02009;h before infection to 4 days after infection with the day of infection defined as 0 day, and equivalent amounts of PBS were given as placebo and control. Six days after infection, the mice lungs were collected for titer and pathological examination. Mice were anaesthetized by isoflurane, and at the end of the experiment, mice were euthanized by carbon dioxide inhalation.</p></sec><sec id="sec2.12"><title>2.12. Statistical Analysis</title><p>The data obtained were analyzed using SPSS (version 13.0). The data were expressed as the mean&#x02009;&#x000b1;&#x02009;SD. Significant differences were obtained by single-tailed Student's <italic>t</italic>-test when comparing two groups. Multiple group comparisons were performed via one-way ANOVA test based on variance homogeneity. All results in which <italic>P</italic> &#x0003c; 0.05 were considered significant.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. LQ Displays Efficacy against Influenza B Viruses In Vitro</title><p>First, a cell proliferation and viability assay based on three independent MTT assays was performed to determine the nonspecific cytotoxicity of LQ for MDCK cells. The 50% toxic concentration (TC<sub>50</sub>) of LQ was 4.0221&#x02009;&#x000b1;&#x02009;0.0471&#x02009;mg/mL (<xref rid="tab1" ref-type="table">Table 1</xref>). There is no significant cellular toxic effect within the concentration range of 0.075&#x02013;1.0&#x02009;mg/mL of LQ in MDCK cells when the medicine and cells were incubated together at 37&#x000b0;C for 48&#x02009;h in a humidified atmosphere of 5% CO<sub>2</sub>. Furthermore, we tested the antiviral activity of LQ against five stains of influenza B viruses: B/Lee/40, three of Victoria-like virus (isolated in 2009, 2012, and 2016), and one of Yamagata-like virus (isolated in 2016). The results (<xref rid="tab1" ref-type="table">Table 1</xref>) showed that LQ exhibited an inhibitory effect on five IBV strains with 50% inhibitive concentrations (IC<sub>50</sub>) ranging from 0.228&#x02009;&#x000b1;&#x02009;0.150 to 0.754&#x02009;&#x000b1;&#x02009;0.161&#x02009;mg/mL, and the selective index (SI) [<xref rid="B18" ref-type="bibr">18</xref>] ranged from 5.3 to 17.6. The inhibitory effect of LQ against the strains isolated in 2016 was more potent than that on the strains isolated before 2012. Interestingly, LQ showed the same inhibitory effect on the two lineages of strains isolated in 2016.</p></sec><sec id="sec3.2"><title>3.2. LQ Inhibits the Early Phase of Influenza B Virus Replication</title><p>According to three treatment models representing prevention (pretreatment of cells, Pre-C), direct action (pretreatment of virus, Pre-V), and therapy (posttreatment, Post-V), the IBV was inhibited by more than 0.15&#x02009;mg/mL of LQ with dose dependence in the pretreatment of virus model and the posttreatment model (<xref ref-type="fig" rid="fig1">Figure 1(a)</xref>), indicating that LQ may play an inhibitory role in both direct and therapeutic models, but not a preventive one. Furthermore in posttreatment model, the time course results (<xref ref-type="fig" rid="fig1">Figure 1(b)</xref>) showed that IBV yield was reduced with treatment with 0.6&#x02009;mg/mL of LQ at 0&#x02013;4&#x02009;h after infection, but treatment was not effective in reducing yield at more than 6&#x02009;h. This demonstrated that LQ inhibits the early stages of viral cycle of IBV.</p></sec><sec id="sec3.3"><title>3.3. LQ Inhibits NP Replication of Influenza B Virus</title><p>To identify the effect of LQ on IBV replication, the synthesis of viral nucleoprotein of infected cells was examined by immunofluorescence. The cells were infected with B/Guangzhou/0215/2012 and then treated with 0.6&#x02009;mg/mL of LQ for 8&#x02009;h. Compared to nontreatment or treatment with the same concentration of medicine solvent (0.12% DMSO), 0.6&#x02009;mg/mL of LQ distinctly decreased the synthesis of nucleoprotein (<xref ref-type="fig" rid="fig1">Figure 1(c)</xref>).</p></sec><sec id="sec3.4"><title>3.4. LQ Inhibits Influenza B Virus Binding to Cell Surface</title><p>To study the antiviral mechanism of LQ in pretreatment of virus, inhibition of HA was evaluated. The HA inhibition assay results (<xref ref-type="fig" rid="fig2">Figure 2</xref>) showed that &#x02265;0.313&#x02009;mg/mL of LQ has HA inhibition activity against B/Guangzhou/0215/2012 but not A/California/04/2009. To confirm this result, indirect immunofluorescence microscopy of viral binding was performed, and there was a similar result (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>); that is, 0.6&#x02009;mg/mL of LQ could inhibit viral binding to MDCK cells for B/Guangzhou/0215/2012 but not for A/California/04/2009.</p></sec><sec id="sec3.5"><title>3.5. LQ Displays Inhibition of Inflammatory Cytokines and Chemokines after Influenza B Virus Infection in mRNA Levels</title><p>Inflammatory cytokine and chemokine expression imbalance will cause tissue damage. Therefore, the effects of LQ on cytokines and chemokines were determined. The results (<xref ref-type="fig" rid="fig3">Figure 3</xref>) showed a significantly increased mRNA level of RANTES (62-fold), IL-6 (99-fold), IL-8 (46-fold), IP-10 (150-fold), TNF-<italic>&#x003b1;</italic> (53-fold), MCP-1 (8.8-fold), MIP-1<italic>&#x003b2;</italic> (58-fold), and IFN-<italic>&#x003bb;</italic>1 (113-fold) in the A549 cells at 12&#x02009;h after IBV infection compared to GAPDH gene. Also, a reduction of all inflammatory factors mRNA level was observed in cells treated with &#x02265;0.15&#x02009;mg/mL of LQ compared to dissolvent treated infected cells. Queerly, a dose-dependent reduction was observed in most of the inflammatory factor mRNA levels except CCL5/RANTES with inverse reduction.</p></sec><sec id="sec3.6"><title>3.6. LQ Reduces the Inflammation of Lungs in Mice Infection Model</title><p>To verify the treatment effect of LQ in vivo, the survival rate was tested at 15 days postinfection; the lung virus yield and lung inflammation (pathological state) were tested at 6 days postinfection in influenza B virus-infected mice. The results (<xref ref-type="fig" rid="fig4">Figure 4</xref>) showed that orally administered LQ (100&#x02013;400&#x02009;mg/kg/day) does not reduce IBV-induced lung viral load and mortality in mice. However, the pathological change in the lungs (<xref ref-type="fig" rid="fig5">Figure 5</xref>) was alleviated to a certain extent. Compared to uninfected mice (<xref ref-type="fig" rid="fig5">Figure 5(a)</xref>), untreated mice showed severe interstitial pneumonia at 6 days after IBV infection (<xref ref-type="fig" rid="fig5">Figure 5(b)</xref>). In the positive control, ribavirin treated mice (<xref ref-type="fig" rid="fig5">Figure 5(c)</xref>), there were a few inflammatory cells around the terminal bronchus. Although interstitial pneumonia was observed in 100&#x02013;400&#x02009;mg/kg/day of LQ treated mice (Figures <xref ref-type="fig" rid="fig5">5(d)</xref>&#x02013;<xref ref-type="fig" rid="fig5">5(f)</xref>), depreciation of inflammatory cells was observed in LQ treated mice lungs compared to the placebo group.</p></sec><sec id="sec3.7"><title>3.7. LQ Combined with Oseltamivir in Infected Mice Model Displays Beneficial Effects</title><p>Because LQ has a weak potency against IBV in individual administration, the effect of the combination of LQ and oseltamivir in IBV-infected mice was tested. The viral titer in lungs (<xref ref-type="fig" rid="fig6">Figure 6</xref>) of infected mice treated with LQ (200&#x02009;mg/kg/day) and oseltamivir (2&#x02009;mg/kg/day) (average value&#x02009;=&#x02009;log 3.67 TCID<sub>50</sub>/g) was lower than the viral titer for mice treated with only LQ at dose of 200&#x02009;mg/kg/day (average value&#x02009;=&#x02009;log 4.5 TCID<sub>50</sub>/g) or mice treated with only oseltamivir at dose of 2&#x02009;mg/kg/day (average value&#x02009;=&#x02009;log 4.5 TCID<sub>50</sub>/g). Interestingly, viral load of 75&#x02009;mg/kg/day of ribavirin treated mice (average value&#x02009;=&#x02009;log 3.17 TCID<sub>50</sub>/g) was lower than that of 50&#x02009;mg/kg/day of oseltamivir (average value&#x02009;=&#x02009;log 3.67 TCID<sub>50</sub>/g).</p><p>The results of the pathological changes in the lungs (<xref ref-type="fig" rid="fig7">Figure 7</xref>) showed that treatment with oseltamivir at doses of 2 and 10&#x02009;mg/kg/day in conjunction with 200&#x02009;mg/kg/day of LQ is better than oseltamivir alone. Severe interstitial pneumonia was observed in untreated mice (<xref ref-type="fig" rid="fig7">Figure 7(c)</xref>), 200&#x02009;mg/kg/day of LQ treated mice (data not showed), and 2&#x02009;mg/kg/day of oseltamivir treated mice (<xref ref-type="fig" rid="fig7">Figure 7(i)</xref>) at 6 days after IBV infection. The lungs of 50&#x02009;mg/kg/day of oseltamivir treated mice (<xref ref-type="fig" rid="fig7">Figure 7(g)</xref>) were similar to those of normal mice (<xref ref-type="fig" rid="fig7">Figure 7(a)</xref>), as well as the mice treated simultaneously with 50&#x02009;mg/kg/day of oseltamivir and 200&#x02009;mg/kg/day of LQ (<xref ref-type="fig" rid="fig7">Figure 7(d)</xref>). Moderate pneumonia was observed in 10&#x02009;mg/kg/day of oseltamivir treated mice (<xref ref-type="fig" rid="fig7">Figure 7(h)</xref>) and 75&#x02009;mg/kg/day of ribavirin treated mice (<xref ref-type="fig" rid="fig7">Figure 7(b)</xref>), and mild pneumonia was observed in mice treated simultaneously with 10&#x02009;mg/kg/day of oseltamivir and 200&#x02009;mg/kg/day of LQ (<xref ref-type="fig" rid="fig7">Figure 7(e)</xref>). Even though severe pneumonia occurs in mice treated simultaneously with 2&#x02009;mg/kg/day of oseltamivir and 200&#x02009;mg/kg/day of LQ (<xref ref-type="fig" rid="fig7">Figure 7(f)</xref>), the inflammatory cells were fewer than those in mice treated with 2&#x02009;mg/kg/day of oseltamivir alone.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>Although influenza B and influenza A are similar, there are many differences between them, particularly the efficiency of antivirus medicines, such as M2 inhibitors and NA inhibitors. This paper describes the effect of LQ against influenza B virus in vitro in a mouse model. We found that LQ has a wide spectrum of antiviral activity against different strains of influenza B virus, including Victoria and Yamagata lineages. Base on the results in vitro, three probable pathways might be deduced for anti-influenza B virus activity of LQ: (a) blockage of viral binding to host receptors; (b) reduction of viral replication; (c) reduction of inflammatory cytokines and chemokines storm reduced by infection.</p><p>First, three antiviral effect models with pretreatment of cells, pretreatment of virus, and posttreatment were performed, the results showed significant inhibitory activity with the pretreatment of virus and posttreatment. A time course also indicated that IBV yield was reduced with LQ treatment at 0&#x02013;4&#x02009;h after infection. It demonstrated that LQ may act as a potent anti-influenza B virus agent at an early stage during the infection, typically the synthesis of NP and assembly into vRNP in nucleus. In this study, NP was localized by immunofluorescence staining. The results showed potent inhibitory effect of LQ against NP synthesis of influenza B virus.</p><p>Virus entry is the first step of infection, and this process is essential and is mediated by surface glycoprotein hemagglutinin (HA) of influenza virus [<xref rid="B19" ref-type="bibr">19</xref>]. There is inhibitory effect of LQ with pretreatment of virus, and it may affect virus HA, blocking virus binding to cell surface. Therefore, we tested whether LQ can inhibit the virus binding. The results clarified that LQ plays a role in the hemagglutination inhibition (HI) activity of influenza B virus (B/Guangzhou/0215/2012) but not influenza A virus (A/California/04/2009). To confirm this result, an immunofluorescence assay for viral binding was performed, and the viral binding of B/Guangzhou/0215/2012 to the MDCK cells surface was reduced by treatment with the LQ, but the same result did not occur in influenza A. The receptor binding site of influenza B virus HA has some significant differences from that of influenza A virus HA [<xref rid="B20" ref-type="bibr">20</xref>]. Also, influenza B virus HA binds to sialic acids with lower affinity than influenza A virus [<xref rid="B21" ref-type="bibr">21</xref>]. We assumed that the reason for this result is whether LQ affects the domain of influenza B HA, which is different from influenza A HA, or the weaker dynamics of influenza B HA. It needs more studies to investigate the mechanisms in the future.</p><p>The cytokines and chemokines evoked by the infection have been shown to contribute to the pathology associated with influenza virus infection [<xref rid="B22" ref-type="bibr">22</xref>]. LQ is a combination of traditional Chinese medicines. In addition to antiviral activity, it may also have anti-inflammatory activity. Influenza virus infection causes cell necrosis/apoptosis, which induces an immune reaction and the production of cytokines. However, the cytokine storm, including the deregulated and exaggerated production of cytokines, usually aggravates the degree of disease [<xref rid="B22" ref-type="bibr">22</xref>]. Our results showed that LQ can inhibit the excessive expression of RANTES, IL-6, IL-8, IP-10, TNF-<italic>&#x003b1;</italic>, MCP-1, MIP-1<italic>&#x003b2;</italic>, and IFN-<italic>&#x003bb;</italic> at the mRNA level and prevent severe inflammation response.</p><p>Animal models are essential in the preclinical evaluation of potential antiviral compounds to investigate safety and efficacy. In contrast to influenza A virus, animal models for the study of influenza B infection are lacking. This lack of studies is due to the limitation of the influenza B host range [<xref rid="B23" ref-type="bibr">23</xref>], which is related to the NS1 protein [<xref rid="B24" ref-type="bibr">24</xref>] and M1 protein [<xref rid="B21" ref-type="bibr">21</xref>]. To evaluate the efficacy of LQ in vivo, we screened the clinical influenza B virus strains and obtained a stable mouse lethal strain, B/Guangzhou/0215/2012 (B0215). In this study, the data of viral load in lungs and survival rates showed that orally administered LQ in the concentration of 400&#x02009;mg/kg/d has no significant protective effect against 5-fold LD<sub>50</sub> B0215&#x02010;infected mice. However, the pathological change in the lungs was alleviated to a certain extent, and there were fewer inflammatory cells in lungs of LQ treated mice compared to mice treated with PBS. Based on our experience of LQ, its effects are multifunctional and mild. According to our previous study of LQ anti-influenza A viruses [<xref rid="B15" ref-type="bibr">15</xref>], lung virus titer was reduced under a high dose (1300&#x02009;mg/kg/d) of LQ in a mouse model of severe pneumonia. In order to investigate the true effects of LQ on influenza B virus, we had developed a ferret model and tree shrew model of influenza B virus [<xref rid="B25" ref-type="bibr">25</xref>]. We will evaluate the antiviral effects of LQ through more indicators, such as fever, activity, and viral load of upper respiratory in the future study.</p><p>In addition to effectiveness, resistance is another issue of concern of anti-influenza drugs. One approach to increasing antiviral potency and reducing resistance emergence is to use combinations of drugs that target different processes [<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>]. Recently, many studies evaluating combinations of agents, including amantadine, oseltamivir, and ribavirin [<xref rid="B28" ref-type="bibr">28</xref>&#x02013;<xref rid="B30" ref-type="bibr">30</xref>] antiviral therapy with anti-inflammatory drugs or antioxidant [<xref rid="B31" ref-type="bibr">31</xref>&#x02013;<xref rid="B33" ref-type="bibr">33</xref>], and antiviral therapy with immunomodulators [<xref rid="B34" ref-type="bibr">34</xref>&#x02013;<xref rid="B36" ref-type="bibr">36</xref>], have been performed. Because LQ has an effect against IBV in individual administration, we speculated that LQ may have potent antiviral activity when combined with other chemical compounds, such as oseltamivir. Our results confirmed that the viral titer in lungs of mice treated with LQ at 200&#x02009;mg/kg/day in combination with oseltamivir at 2&#x02009;mg/kg/day was lower than that in mice treated with either LQ or oseltamivir alone. The viral load and inflammation in lungs of influenza B-infected mice were significantly reduced when 200&#x02009;mg/kg/day of LQ was administered simultaneously with 2&#x02009;mg/kg/day of oseltamivir for five days. However, we have not tested the combinations of the treatments in vitro yet.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Prof. Malik J. S. Peilis and Dr. Feng Ye for gift of viruses. Also, the authors thank Professor Mark Zanin for English language editing of this article. This work was supported by Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Shijiazhuang, China), National Natural Science Foundation of China (NSFC-FDCT-81661168012), Guangdong Science and Technology Department (2013B051000085), Engineering Technology Research Center (Development) of Guangdong General Universities (GCZX-A1408), and Natural Science Basic Research Program of Shaanxi (Program No. 2019JM-513).</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>All the data supporting the results of this study are included within the article.</p></sec><sec><title>Disclosure</title><p>The funders have no direct involvement in study design or data collection, analysis, and interpretation. The study design and manuscript writing were conducted independently by the authors.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec><title>Authors' Contributions</title><p>Chunguang Yang, Yutao Wang, and Jiayang He contributed equally to this work.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>P. K.</given-names></name><name><surname>Chan</surname><given-names>M. C.</given-names></name><name><surname>Cheung</surname><given-names>J. L.</given-names></name><etal/></person-group><article-title>Influenza B lineage circulation and hospitalization rates in a subtropical city, Hong Kong, 2000&#x02013;2010</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2012</year><volume>56</volume><issue>5</issue><fpage>677</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">23074315</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>W. W.</given-names></name><name><surname>Moore</surname><given-names>M. R.</given-names></name><name><surname>Weintraub</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Estimating influenza-associated deaths in the United States</article-title><source><italic toggle="yes">American Journal of Public Health</italic></source><year>2009</year><volume>99</volume><issue>S2</issue><fpage>S225</fpage><lpage>S230</lpage><pub-id pub-id-type="doi">10.2105/ajph.2008.151944</pub-id><pub-id pub-id-type="other">2-s2.0-70350056626</pub-id><pub-id pub-id-type="pmid">19797736</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>L.</given-names></name><name><surname>Shay</surname><given-names>D. K.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Influenza-associated mortality in temperate and subtropical Chinese cities, 2003&#x02013;2008</article-title><source><italic toggle="yes">Bulletin of the World Health Organization</italic></source><year>2012</year><volume>90</volume><issue>4</issue><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.2471/blt.11.096958</pub-id><pub-id pub-id-type="other">2-s2.0-84859397302</pub-id><pub-id pub-id-type="pmid">22511824</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>J.-H.</given-names></name><name><surname>Na</surname><given-names>J.-Y.</given-names></name><name><surname>Kim</surname><given-names>J.-H.</given-names></name><etal/></person-group><article-title>Neurological and muscular manifestations associated with influenza B infection in children</article-title><source><italic toggle="yes">Pediatric Neurology</italic></source><year>2013</year><volume>49</volume><issue>2</issue><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2013.04.004</pub-id><pub-id pub-id-type="other">2-s2.0-84880315400</pub-id><pub-id pub-id-type="pmid">23859854</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thabet</surname><given-names>F. I.</given-names></name><name><surname>Khalil</surname><given-names>S.</given-names></name><name><surname>Naz</surname><given-names>F.</given-names></name><name><surname>Dyme</surname><given-names>I. Z.</given-names></name></person-group><article-title>Cerebellar mutism and reversible cytotoxic edema in influenza B-associated encephalopathy</article-title><source><italic toggle="yes">Pediatric Neurology</italic></source><year>2013</year><volume>49</volume><issue>6</issue><fpage>489</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2013.06.014</pub-id><pub-id pub-id-type="other">2-s2.0-84888262458</pub-id><pub-id pub-id-type="pmid">24095574</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>H.</given-names></name><name><surname>Wittekind</surname><given-names>C.</given-names></name><name><surname>Liebert</surname><given-names>U. G.</given-names></name><etal/></person-group><article-title>Lethal influenza B myocarditis in a child and review of the literature for pediatric age groups</article-title><source><italic toggle="yes">Infection</italic></source><year>2010</year><volume>38</volume><issue>3</issue><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1007/s15010-010-0013-4</pub-id><pub-id pub-id-type="other">2-s2.0-77953232426</pub-id><pub-id pub-id-type="pmid">20358246</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paddock</surname><given-names>C. D.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Denison</surname><given-names>A. M.</given-names></name><etal/></person-group><article-title>Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2012</year><volume>205</volume><issue>6</issue><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir861</pub-id><pub-id pub-id-type="other">2-s2.0-84863229862</pub-id><pub-id pub-id-type="pmid">22291193</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>F. G.</given-names></name><name><surname>Jennings</surname><given-names>L.</given-names></name><name><surname>Robson</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Oral oseltamivir in human experimental influenza B infection</article-title><source><italic toggle="yes">Antiviral Therapy</italic></source><year>2000</year><volume>5</volume><issue>3</issue><fpage>205</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">11075941</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnham</surname><given-names>A. J.</given-names></name><name><surname>Baranovich</surname><given-names>T.</given-names></name><name><surname>Govorkova</surname><given-names>E. A.</given-names></name></person-group><article-title>Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2013</year><volume>100</volume><issue>2</issue><fpage>520</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.08.023</pub-id><pub-id pub-id-type="other">2-s2.0-84885569081</pub-id><pub-id pub-id-type="pmid">24013000</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>M.</given-names></name><name><surname>Saito</surname><given-names>R.</given-names></name><name><surname>Sato</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan</article-title><source><italic toggle="yes">The Tohoku Journal of Experimental Medicine</italic></source><year>2008</year><volume>214</volume><issue>2</issue><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1620/tjem.214.113</pub-id><pub-id pub-id-type="other">2-s2.0-41949083517</pub-id><pub-id pub-id-type="pmid">18285668</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugaya</surname><given-names>N.</given-names></name><name><surname>Mitamura</surname><given-names>K.</given-names></name><name><surname>Yamazaki</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2007</year><volume>44</volume><issue>2</issue><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1086/509925</pub-id><pub-id pub-id-type="other">2-s2.0-33846138361</pub-id><pub-id pub-id-type="pmid">17173216</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>N.</given-names></name><name><surname>Ikematsu</surname><given-names>H.</given-names></name><name><surname>Iwaki</surname><given-names>N.</given-names></name><etal/></person-group><article-title>A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2006</year><volume>43</volume><issue>4</issue><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1086/505868</pub-id><pub-id pub-id-type="other">2-s2.0-33746634739</pub-id><pub-id pub-id-type="pmid">16838232</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.-F.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Anti-influenza agents from traditional Chinese medicine</article-title><source><italic toggle="yes">Natural Product Reports</italic></source><year>2010</year><volume>27</volume><issue>12</issue><fpage>1758</fpage><lpage>1780</lpage><pub-id pub-id-type="doi">10.1039/c0np00005a</pub-id><pub-id pub-id-type="other">2-s2.0-78649262032</pub-id><pub-id pub-id-type="pmid">20941447</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>Z.</given-names></name><name><surname>Jia</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial</article-title><source><italic toggle="yes">Chinese Medical Journal</italic></source><year>2011</year><volume>124</volume><issue>18</issue><fpage>2925</fpage><lpage>2933</lpage><pub-id pub-id-type="pmid">22040504</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><etal/></person-group><article-title>The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function</article-title><source><italic toggle="yes">BMC Complementary and Alternative Medicine</italic></source><year>2017</year><volume>17</volume><issue>1</issue><fpage>p. 130</fpage><pub-id pub-id-type="doi">10.1186/s12906-017-1585-7</pub-id><pub-id pub-id-type="other">2-s2.0-85013834593</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>L. J.</given-names></name><name><surname>Muench</surname><given-names>H.</given-names></name></person-group><article-title>A simple method of estimating fifty per cent endpoints</article-title><source><italic toggle="yes">American Journal of Epidemiology</italic></source><year>1938</year><volume>27</volume><issue>3</issue><fpage>493</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a118408</pub-id><pub-id pub-id-type="other">2-s2.0-33745158157</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Inhibition of influenza virus via a sesquiterpene fraction isolated from Laggera pterodonta by targeting the NF-<italic>&#x003ba;</italic>B and p38 pathways</article-title><source><italic toggle="yes">BMC Complementary and Alternative Medicine</italic></source><year>2017</year><volume>17</volume><issue>1</issue><fpage>p. 25</fpage><pub-id pub-id-type="doi">10.1186/s12906-016-1528-8</pub-id><pub-id pub-id-type="other">2-s2.0-85008411915</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Lariciresinol-4-O-<italic>&#x003b2;</italic>-D-glucopyranoside from the root of Isatis indigotica inhibits influenza A virus-induced pro-inflammatory response</article-title><source><italic toggle="yes">Journal of Ethnopharmacology</italic></source><year>2015</year><volume>174</volume><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2015.08.037</pub-id><pub-id pub-id-type="other">2-s2.0-84940988599</pub-id><pub-id pub-id-type="pmid">26320688</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Q.</given-names></name><name><surname>Sivaramakrishna</surname><given-names>R. P.</given-names></name><name><surname>Ludwig</surname><given-names>K.</given-names></name><name><surname>Korte</surname><given-names>T.</given-names></name><name><surname>B&#x000f6;ttcher</surname><given-names>C.</given-names></name><name><surname>Herrmann</surname><given-names>A.</given-names></name></person-group><article-title>Early steps of the conformational change of influenza virus hemagglutinin to a fusion active state: stability and energetics of the hemagglutinin</article-title><source><italic toggle="yes">Biochimica et Biophysica Acta (BBA)-Biomembranes</italic></source><year>2003</year><volume>1614</volume><issue>1</issue><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/s0005-2736(03)00158-5</pub-id><pub-id pub-id-type="other">2-s2.0-0037811025</pub-id><pub-id pub-id-type="pmid">12873761</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koutsakos</surname><given-names>M.</given-names></name><name><surname>Nguyen</surname><given-names>T. H.</given-names></name><name><surname>Barclay</surname><given-names>W. S.</given-names></name><name><surname>Kedzierska</surname><given-names>K.</given-names></name></person-group><article-title>Knowns and unknowns of influenza B viruses</article-title><source><italic toggle="yes">Future Microbiology</italic></source><year>2016</year><volume>11</volume><issue>1</issue><fpage>119</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.2217/fmb.15.120</pub-id><pub-id pub-id-type="other">2-s2.0-84952651772</pub-id><pub-id pub-id-type="pmid">26684590</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullers</surname><given-names>J. A.</given-names></name><name><surname>Hoffmann</surname><given-names>E.</given-names></name><name><surname>Huber</surname><given-names>V. C.</given-names></name><name><surname>Nickerson</surname><given-names>A. D.</given-names></name></person-group><article-title>A single amino acid change in the C-terminal domain of the matrix protein M1 of influenza B virus confers mouse adaptation and virulence</article-title><source><italic toggle="yes">Virology</italic></source><year>2005</year><volume>336</volume><issue>2</issue><fpage>318</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.03.028</pub-id><pub-id pub-id-type="other">2-s2.0-18844448981</pub-id><pub-id pub-id-type="pmid">15892972</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Gruta</surname><given-names>N. L.</given-names></name><name><surname>Kedzierska</surname><given-names>K.</given-names></name><name><surname>Stambas</surname><given-names>J.</given-names></name><name><surname>Doherty</surname><given-names>P. C.</given-names></name></person-group><article-title>A question of self-preservation: immunopathology in influenza virus infection</article-title><source><italic toggle="yes">Immunology &#x00026; Cell Biology</italic></source><year>2007</year><volume>85</volume><issue>2</issue><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1038/sj.icb.7100026</pub-id><pub-id pub-id-type="other">2-s2.0-33947108477</pub-id><pub-id pub-id-type="pmid">17213831</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>D.</given-names></name><name><surname>Elderfield</surname><given-names>R. A.</given-names></name><name><surname>Barclay</surname><given-names>W. S.</given-names></name></person-group><article-title>Molecular studies of influenza B virus in the reverse genetics era</article-title><source><italic toggle="yes">Journal of General Virology</italic></source><year>2011</year><volume>92</volume><issue>1</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1099/vir.0.026187-0</pub-id><pub-id pub-id-type="other">2-s2.0-78651253025</pub-id><pub-id pub-id-type="pmid">20926635</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>L.-C.</given-names></name><name><surname>Leonard</surname><given-names>P. G.</given-names></name><etal/></person-group><article-title>Structural basis for the sequence-specific recognition of human ISG15 by the NS1 protein of influenza B virus</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2011</year><volume>108</volume><issue>33</issue><fpage>13468</fpage><lpage>13473</lpage><pub-id pub-id-type="doi">10.1073/pnas.1107032108</pub-id><pub-id pub-id-type="other">2-s2.0-80051970948</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Xia</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The tree shrew is a promising model for the study of influenza B virus infection</article-title><source><italic toggle="yes">Virology Journal</italic></source><year>2019</year><volume>16</volume><fpage>p. 77</fpage><pub-id pub-id-type="doi">10.1186/s12985-019-1171-3</pub-id><pub-id pub-id-type="other">2-s2.0-85067038208</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>F. G.</given-names></name></person-group><article-title>Combination antiviral therapy for respiratory virus infections</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>1996</year><volume>29</volume><issue>1</issue><fpage>45</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/0166-3542(95)00914-0</pub-id><pub-id pub-id-type="other">2-s2.0-0029867750</pub-id><pub-id pub-id-type="pmid">8721543</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunning</surname><given-names>J.</given-names></name><name><surname>Baillie</surname><given-names>J. K.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Hayden</surname><given-names>F. G.</given-names></name></person-group><article-title>Antiviral combinations for severe influenza</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2014</year><volume>14</volume><issue>12</issue><fpage>1259</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(14)70821-7</pub-id><pub-id pub-id-type="other">2-s2.0-84922726229</pub-id><pub-id pub-id-type="pmid">25213733</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>J. H.</given-names></name><name><surname>Bao</surname><given-names>Y.</given-names></name><name><surname>Beeler</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2017</year><volume>17</volume><issue>12</issue><fpage>1255</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(17)30476-0</pub-id><pub-id pub-id-type="other">2-s2.0-85029765631</pub-id><pub-id pub-id-type="pmid">28958678</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>J. T.</given-names></name><name><surname>Smee</surname><given-names>D. F.</given-names></name><name><surname>Barnard</surname><given-names>D. L.</given-names></name><etal/></person-group><article-title>Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2012</year><volume>7</volume><issue>1</issue><pub-id pub-id-type="publisher-id">e31006</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0031006</pub-id><pub-id pub-id-type="other">2-s2.0-84856078603</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smee</surname><given-names>D. F.</given-names></name><name><surname>Wong</surname><given-names>M.-H.</given-names></name><name><surname>Bailey</surname><given-names>K. W.</given-names></name><name><surname>Sidwell</surname><given-names>R. W.</given-names></name></person-group><article-title>Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses</article-title><source><italic toggle="yes">Antiviral Chemistry and Chemotherapy</italic></source><year>2006</year><volume>17</volume><issue>4</issue><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1177/095632020601700403</pub-id><pub-id pub-id-type="other">2-s2.0-33947105014</pub-id><pub-id pub-id-type="pmid">17066897</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>A. J.</given-names></name><etal/></person-group><article-title>Avian influenza A H7N9 virus induces severe pneumonia in mice without prior adaptation and responds to a combination of zanamivir and COX-2 inhibitor</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2014</year><volume>9</volume><issue>9</issue><pub-id pub-id-type="publisher-id">e107966</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0107966</pub-id><pub-id pub-id-type="other">2-s2.0-84907210256</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottolini</surname><given-names>M.</given-names></name><name><surname>Blanco</surname><given-names>J.</given-names></name><name><surname>Porter</surname><given-names>D.</given-names></name><name><surname>Peterson</surname><given-names>L.</given-names></name><name><surname>Curtis</surname><given-names>S.</given-names></name><name><surname>Prince</surname><given-names>G.</given-names></name></person-group><article-title>Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model</article-title><source><italic toggle="yes">Pediatric Pulmonology</italic></source><year>2003</year><volume>36</volume><issue>4</issue><fpage>290</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1002/ppul.10320</pub-id><pub-id pub-id-type="other">2-s2.0-0141520652</pub-id><pub-id pub-id-type="pmid">12950040</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghezzi</surname><given-names>P.</given-names></name><name><surname>Ungheri</surname><given-names>D.</given-names></name></person-group><article-title>Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model</article-title><source><italic toggle="yes">International Journal of Immunopathology and Pharmacology</italic></source><year>2004</year><volume>17</volume><issue>1</issue><fpage>99</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1177/039463200401700114</pub-id><pub-id pub-id-type="other">2-s2.0-5444230301</pub-id><pub-id pub-id-type="pmid">15000873</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quispe-Laime</surname><given-names>A. M.</given-names></name><name><surname>Bracco</surname><given-names>J. D.</given-names></name><name><surname>Barberio</surname><given-names>P. A.</given-names></name><etal/></person-group><article-title>H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment</article-title><source><italic toggle="yes">Intensive Care Medicine</italic></source><year>2010</year><volume>36</volume><issue>1</issue><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s00134-009-1727-6</pub-id><pub-id pub-id-type="other">2-s2.0-76549126643</pub-id><pub-id pub-id-type="pmid">19924393</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A. J. X.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>To</surname><given-names>K. K. W.</given-names></name><etal/></person-group><article-title>Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB/c mice</article-title><source><italic toggle="yes">Clinical and Vaccine Immunology</italic></source><year>2014</year><volume>21</volume><issue>4</issue><fpage>570</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1128/cvi.00816-13</pub-id><pub-id pub-id-type="other">2-s2.0-84897937018</pub-id><pub-id pub-id-type="pmid">24521786</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haasbach</surname><given-names>E.</given-names></name><name><surname>Hartmayer</surname><given-names>C.</given-names></name><name><surname>Planz</surname><given-names>O.</given-names></name></person-group><article-title>Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2013</year><volume>98</volume><issue>2</issue><fpage>319</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.03.006</pub-id><pub-id pub-id-type="other">2-s2.0-84876003945</pub-id><pub-id pub-id-type="pmid">23523553</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Influenza B virus yield after treatment with LQ. (a) The effect of treatment with LQ against influenza B virus in different models: Pre-C, pretreatment of cells with LQ; Pre-V, pretreatment of virus with LQ; Post-V, posttreatment after infection. UD: under detection. (b) The time course assay: cells were treated with 0.6&#x02009;mg/mL of LQ after infection with B0215 (MOI&#x02009;=&#x02009;0.01); the supernatant was collected and titrated after two days. The dotted line is the value which detected limitation. <sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05, <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01 compared to treatment with 0.12% DMSO (the concentration of 0.6&#x02009;mg/mL of LQ). (c) Immunofluorescence assay for nucleoprotein expression of influenza B virus. Cells were infected with B0215 at 0.1&#x02009;MOI for 90&#x02009;min at 4&#x000b0;C; the viral solution was replaced with medium containing 1&#x02009;<italic>&#x003bc;</italic>g/mL of TPCK treated trypsin, LQ (0.6&#x02009;mg/mL), or 0.12% DMSO. The cells were fixed and immunofluorescence assay was performed at 8&#x02009;h after infection.</p></caption><graphic xlink:href="ECAM2020-3196375.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>LQ might target viral binding activity of influenza B virus B0215. (a) Influenza virus hemagglutination inhibition assay after treatment with LQ. (b) Immunofluorescence assay for influenza B virus and influenza A virus viral binding after treatment with 0.6&#x02009;mg/mL of LQ or the same concentration of DMSO for 1&#x02009;h.</p></caption><graphic xlink:href="ECAM2020-3196375.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>The effect of cytokine mRNA expression level in influenza B virus-infected A549&#x02009;cells after treatment with Lianhua-Qingwen. <sup><italic>&#x02217;&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.001 compared to control via <italic>t</italic>-test. (a) CCL-5/RANTES. (b) IL6. (c) CXCL8/IL8. (d) CXCL10/IP-10. (e) TNF-<italic>&#x003b1;</italic>. (f) CCL2/MCP-1. (g) CCL4/MIP-1<italic>&#x003b2;</italic>. (h) IFN-<italic>&#x003bb;</italic>1.</p></caption><graphic xlink:href="ECAM2020-3196375.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The survival and viral titer in lungs of B0215&#x02010;infected mice after treatment with LQ. (a) Weight change after treatment. (b) Survival after treatment. (c) Viral titer in lungs after treatment. The dotted line is limited detection (LD). <sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05 compared to placebo via <italic>t</italic>-test.</p></caption><graphic xlink:href="ECAM2020-3196375.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>The pathological change of B0215&#x02010;infected mice lungs after treatment with LQ. (a) Uninfected. (b) Placebo. (c) Treated with 75&#x02009;mg/kg/day of ribavirin. (d&#x02013;f) Treated with 100, 200, and 400&#x02009;mg/kg/day of LQ, respectively (100x).</p></caption><graphic xlink:href="ECAM2020-3196375.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>The viral load in lungs of B0215&#x02010;infected mice treated with LQ combined with oseltamivir. The dotted line is the value which detected limitation. <sup><italic>&#x02217;&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.01, <sup><italic>&#x02217;</italic></sup><italic>P</italic> &#x0003c; 0.05 compared to placebo via <italic>t</italic>-test.</p></caption><graphic xlink:href="ECAM2020-3196375.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>The pathological change of infected mice lungs treated with LQ combined with oseltamivir after infection with influenza B. (a) Uninfected. (b) Treated with 75&#x02009;mg/kg/day of ribavirin. (c) Placebo. (d&#x02013;f) Treated with 200&#x02009;mg/kg/day of LQ combined with 50/10/2&#x02009;mg/kg/day of oseltamivir. (g&#x02013;i) Treated with 50/10/2&#x02009;mg/kg/day of oseltamivir.</p></caption><graphic xlink:href="ECAM2020-3196375.007"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Anti-influenza B virus activity of Lianhua-Qingwen capsule.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Viruses</th><th align="center" rowspan="1" colspan="1">TC<sub>50</sub> (mg/mL)</th><th align="center" rowspan="1" colspan="1">IC<sub>50</sub> (mg/mL)</th><th align="center" rowspan="1" colspan="1">SI</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">B/Lee/40</td><td rowspan="5" align="center" colspan="1">4.0221&#x02009;&#x000b1;&#x02009;0.0471</td><td align="center" rowspan="1" colspan="1">0.625&#x02009;&#x000b1;&#x02009;0.131</td><td align="center" rowspan="1" colspan="1">6.4</td></tr><tr><td align="left" rowspan="1" colspan="1">B/Guangzhou/GIRD08/2009<sup>v</sup></td><td align="center" rowspan="1" colspan="1">0.754&#x02009;&#x000b1;&#x02009;0.161</td><td align="center" rowspan="1" colspan="1">5.3</td></tr><tr><td align="left" rowspan="1" colspan="1">B/Guangzhou/GIRD01/2016<sup>v</sup></td><td align="center" rowspan="1" colspan="1">0.228&#x02009;&#x000b1;&#x02009;0.150</td><td align="center" rowspan="1" colspan="1">17.6</td></tr><tr><td align="left" rowspan="1" colspan="1">B/Guangzhou/0215/2012<sup>v</sup></td><td align="center" rowspan="1" colspan="1">0.487&#x02009;&#x000b1;&#x02009;0.187</td><td align="center" rowspan="1" colspan="1">14.0</td></tr><tr><td align="left" rowspan="1" colspan="1">B/Guangzhou/19/2016<sup>y</sup></td><td align="center" rowspan="1" colspan="1">0.298&#x02009;&#x000b1;&#x02009;0.078</td><td align="center" rowspan="1" colspan="1">13.5</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>v</sup>Victoria-like virus, <sup>y</sup>Yamagata-like virus.</p></fn></table-wrap-foot></table-wrap></floats-group></article>